

---

IMPORTANT

---



## CHINA PIONEER PHARMA HOLDINGS LIMITED

中国先锋医药控股有限公司

(incorporated in the Cayman Islands with limited liability)

### GLOBAL OFFERING

Number of Offer Shares under the Global Offering : 333,334,000 Shares (subject to adjustment and the Over-allotment Option)  
Number of Hong Kong Offer Shares : 33,334,000 Shares (subject to adjustment)  
Number of International Offer Shares : 300,000,000 Shares (subject to adjustment and the Over-allotment Option)  
Maximum Offer Price : HK\$5.00 per Share plus brokerage of 1.0%, SFC transaction levy of 0.003% and the Hong Kong Stock Exchange trading fee of 0.005% (payable in full on application, subject to refund)  
Nominal value : US\$0.01 per Share  
Stock code : 01345

*Sole Global Coordinator and Sole Sponsor*



*Joint Bookrunners and Joint Lead Managers*



*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this prospectus, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this prospectus.*

*A copy of this prospectus, having attached thereto the documents specified in the paragraph headed "Documents Delivered to the Registrar of Companies in Hong Kong" in Appendix V to this prospectus, has been registered by the Registrar of Companies in Hong Kong as required by section 342C of the Companies Ordinance (Chapter 32 of the Laws of Hong Kong). The Securities and Futures Commission and the Registrar of Companies in Hong Kong take no responsibility for the contents of this prospectus or any other document referred to above.*

*The Offer Price is expected to be fixed by agreement between the Sole Global Coordinator (on behalf of the Underwriters) and us (for ourselves and on behalf of the Option Grantor) on the Price Determination Date. The Price Determination Date is expected to be on or around Tuesday, 29 October 2013 and, in any event, not later than Friday, 1 November 2013. The Offer Price will not be more than HK\$5.00 and is currently expected to be not less than HK\$4.10. Investors applying for Hong Kong Offer Shares must pay on application, the maximum Offer Price of HK\$5.00 for each Share together with a brokerage of 1.0%, SFC transaction levy of 0.003% and the Hong Kong Stock Exchange trading fee of 0.005%.*

*The Sole Global Coordinator (on behalf of the Underwriters) may reduce the number of Offer Shares and/or the indicative offer price range below that stated in this prospectus (which is HK\$4.10 to HK\$5.00 per Offer Share) at any time prior to the morning of the last day for lodging applications under the Hong Kong Public Offering. In such case, notices of the reduction in the number of Offer Shares and/or the indicative offer price range will be published in South China Morning Post (in English) and Hong Kong Economic Times (in Chinese) not later than the morning of the last day for lodging applications under the Hong Kong Public Offering. Such notice will also be available at the website of the Hong Kong Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk) and our website at [www.pioneer-pharma.com](http://www.pioneer-pharma.com).*

*If, for any reason, the Sole Global Coordinator (on behalf of the Underwriters) and we (for ourselves and on behalf of the Option Grantor) are unable to reach an agreement on the Offer Price by Friday, 1 November 2013, the Global Offering will not become unconditional and will lapse immediately. The obligations of the Hong Kong Underwriters under the Hong Kong Underwriting Agreement to subscribe for, and to procure subscribers for, the Hong Kong Offer Shares, are subject to termination by the Sole Global Coordinator (on behalf of the Hong Kong Underwriters) if certain events shall occur prior to 8:00 a.m. on Tuesday, 5 November 2013. Such grounds are set out in the section headed "Underwriting" of this prospectus. It is important that you refer to that section for further details.*

*The Shares have not been and will not be registered under the U.S. Securities Act and, subject to certain exceptions, may not be offered or sold in the United States.*

24 October 2013